Skip to Content

'
Yasuhiro Oki, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2012
Phone: 713-792-2860

Education & Training

Degree-Granting Education

1998 Faculty of Medicine, University of Tokyo, Tokyo, Japan, MD, Medicine

Postgraduate Training

7/2003-6/2006 Clinical Fellowship, Medical Oncology and Hematology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, Robert A. Wolff
7/2000-6/2003 Clinical Residency, Internal Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY, Ethan Fried
4/1998-3/2000 Clinical Residency, Internal Medicine, Toranomon Hospital, Tokyo, Japan, Yoshitomo Muto

Board Certifications

10/2008 American Board of Hematology
10/2006 American Board of Medical Oncology
8/2003 American Board of Internal Medicine

Experience/Service

Academic Appointments

Chief Physician (09/2007-08/2010), Aichi Cancer Center, Nagoya, Japan, 9/2006-8/2010

Selected Publications

Peer-Reviewed Original Research Articles

1. Oki Y, Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther 12(5):623-32, 5/2012. e-Pub 3/2012. PMID: 22428917.
2. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/2012. e-Pub 2/2012. PMCID: PMC3359733.
3. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 3/2012. PMID: 22383790.
4. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12(13):1222-8, 12/2011. PMID: 22033282.
5. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, de Castro Faria S, Jeffrey Medeiros L, Ivy P, Younes A. Clinical Experience with the Heat Shock Protein-90 inhibitor, Tanespimycin (17AAG), in Patients with Relapsed Lymphoma. Leuk Lymphoma. e-Pub 10/2011. PMID: 21988665.
6. Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. e-Pub 7/2011. PMID: 21745170.
7. Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 4(3):245-52, 6/2011. PMID: 21668391.
8. Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, Morishima Y. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol 93(4):502-8, 4/2011. e-Pub 4/2011. PMID: 21512731.
9. Estécio MR, Gallegos J, Vallot C, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JP. Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res 20(10):1369-82, 10/2010. e-Pub 8/2010. PMCID: PMC2945186.
10. Kato H, Yamamoto K, Matsuo K, Oki Y, Taji H, Kuwatsuka Y, Seto M, Kagami Y, Morishima Y. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol 21(8):1699-705, 8/2010. e-Pub 2/2010. PMID: 20172906.
11. Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep 5(3):135-9, 7/2010. PMID: 20490723.
12. Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H, Kagami Y, Yamamoto K, Morishima Y. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. Eur J Haematol 84(6):493-8, 6/2010. e-Pub 2/2010. PMID: 20148943.
13. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28(4):605-13, 2/2010. e-Pub 12/2009. PMCID: PMC2815995.
14. Chihara D, Kagami Y, Oki Y, Kato H, Onoda H, Ine S, Taji H, Yamamoto K, Morishima Y. R-CHOP therapy for MALT lymphoma of the rectum. Eur J Haematol 84(1):84-6, 1/2010. e-Pub 9/2009. PMID: 19737307.
15. Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima Y. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 50(12):1999-2004, 12/2009. PMID: 19860627.
16. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 11/2009. e-Pub 9/2009. PMID: 19770379.
17. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15(11):3881-8, 6/2009. e-Pub 5/2009. PMID: 19470736.
18. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 81(6):448-53, 12/2008. e-Pub 8/2008. PMID: 18691256.
19. Oki Y, Kato H, Matsuo K, Kuwatsuka Y, Taji H, Yamamoto K, Kagami Y, Morishima Y. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma 49(7):1345-51, 7/2008. PMID: 18452099.
20. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111(4):2382-4, 2/2008. e-Pub 11/2007. PMCID: PMC2234065.
21. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2/2008. PMID: 18085611.
22. Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 99(1):179-84, 1/2008. e-Pub 11/2007. PMID: 17991293.
23. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma 48(9):1869-71, 9/2007. PMID: 17786728.
24. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics 63(2):429-36, 6/2007. PMID: 17688495.
25. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109(5):899-906, 3/2007. PMID: 17236224.
26. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 92(2):269-70, 2/2007. PMID: 17296586.
27. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 1/2007. PMID: 17133412.
28. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 1/2007. e-Pub 8/2006. PMID: 16882708.
29. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 91(8):1147-8, 8/2006. e-Pub 7/2006. PMID: 16870548.
30. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 66(10):5077-84, 5/2006. PMID: 16707430.
31. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2/2006. e-Pub 8/2005. PMID: 16123215.
32. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370-3, 11/2005. e-Pub 7/2005. PMCID: PMC1895065.
33. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 104(4):781-7, 8/2005. PMID: 15973667.

Invited Articles

1. Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 49(5):883-9, 5/2008. PMID: 18452104.
2. Oki Y, Issa JP. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol 86(4):306-14, 11/2007. PMID: 18055336.
3. Oki Y, Aoki E, Issa JP. Decitabine--bedside to bench. Crit Rev Oncol Hematol 61(2):140-52, 2/2007. e-Pub 10/2006. PMID: 17023173.
4. Oki Y, Issa JP. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials 1(2):169-82, 5/2006. PMID: 18473969.
5. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines 3(4):403-11, 8/2004. PMID: 15270645.

Editorials

1. Oki Y, Younes A. Endothelial progenitor cells in non-Hodgkin's lymphoma. Haematologica 92(4):433-4, 4/2007. PMID: 17488651.

Letters to the Editor

1. Oki Y, Kami M, Muto Y. Long-term survival after bone marrow transplantation. N Engl J Med 341(18):1394; author reply 1395, 10/1999. PMID: 10577087.

Grant & Contract Support

Title: Analysis of Epigenetic Patterns in Patients with MDS who are Treated with Decitabine
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Postdoctoral Fellow

Last updated: 6/3/2013